Actelion presents its strategy for value creation
(Thomson Reuters ONE) -
Actelion Pharmaceuticals Ltd /
Actelion presents its strategy for value creation
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
ALLSCHWIL/BASEL, SWITZERLAND - 08 May 2012 - Actelion (SIX: ATLN) will today
outline the company's three key strategic elements for value creation at an
investor event in London.
1) Expanding Actelion's leadership in the PAH market
Actelion is well positioned to expand its leadership in the PAH market following
the recent successful conclusion of the landmark SERAPHIN morbidity/mortality
study with macitentan in patients suffering from pulmonary arterial
hypertension.
Actelion's new product pipeline in PAH also includes selexipag, a novel
prostacyclin-IP receptor agonist, currently evaluated in a Phase III
morbidity/mortality study.
2) Refocusing R&D on specialty areas
Actelion will refocus its future R&D activities towards specialty markets.
Actelion's current clinical pipeline in immunomodulation and antibiotics
provides the company with an opportunity to build a second specialty business
franchise, thus accelerating revenue growth and diversifying Actelion's risk
profile.
3) Accelerating cost saving initiatives
Refocusing of Actelion's research and development efforts into specialty areas
is expected to result in lower and more targeted R&D spending, as well as lower
overhead costs. This is in addition to Actelion's ongoing cost saving program.
Financial Outlook: The execution of Actelion's strategy for value creation is
expected - unforeseen events excluded - to produce stable core earnings in 2013
(in local currencies), followed by a return to growth in 2014 and accelerating
to double digit growth in 2015.
Jean-Paul Clozel, MD and Chief Executive Officer of Actelion commented: "I am
committed to value creation for our shareholders. After the promising macitentan
results, Actelion will more than ever continue its effort in the PAH market. The
strength of our pipeline and our renewed efforts to optimize profitability will
produce a bright future for Actelion."
The complete company update presentation is scheduled in London on Tuesday, 08
May 2012, at 10.00 CEST/ 09.00 BST/ 4.00 a.m. EST and is also made available on
the company website, www.actelion.com.
###
Company Update Conference Call / Audiocast details:
Date/Time:
08 May 2012 10.00 hrs - 11.30 hrs Basel (CEST)
09.00 hrs - 10.30 hrs UK (BST)
04.00 a.m. - 5.30 a.m. US (EST)
Conference Call Connect #:
Dial-in participants should start calling the number below 10-15 minutes before
the conference is due to start.
Dial: Europe: +41 (0)44 580 00 74
UK: +44 (0)203 367 94 53
US: +1 866 907 59 23
Participant's mode:
Listen-Only
Audiocast Access:
Audiocast participants should visit the Actelion website www.actelion.com 10-15
minutes before the conference is due to start.
If you experience any access problems go directly to the URL: http://view-
w.tv/p/120-121-11206/en
Participant's mode:
Listen only
Audiocast Replay:
The archived Investor Audiocast will be available for replay through
http://www.actelion.com approximately 60 minutes after the call has ended.
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in
Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally
available dual endothelin receptor antagonist, has been approved as a therapy
for pulmonary arterial hypertension. Actelion markets Tracleer through its own
subsidiaries in key markets worldwide, including the United States (based in
South San Francisco), the European Union, Japan, Canada, Australia and
Switzerland. Actelion, founded in late 1997, is a leading player in innovative
science related to the endothelium - the single layer of cells separating every
blood vessel from the blood stream. Actelion's over 2,500 employees focus on the
discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker
symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index
SMI®).
For further information please contact:
Roland Haefeli
Senior Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
www.actelion.com
The above information contains certain "forward-looking statements", relating to
the company's business, which can be identified by the use of forward-looking
terminology such as "estimates", "believes", "expects", "may", "are expected
to", "will", "will continue", "should", "would be", "seeks", "pending" or
"anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment
and research and development programs and anticipated expenditures in connection
therewith, descriptions of new products expected to be introduced by the company
and anticipated customer demand for such products and products in the company's
existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties
and assumptions. Many factors could cause the actual results, performance or
achievements of the company to be materially different from any future results,
performances or achievements that may be expressed or implied by such forward-
looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those described herein as anticipated, believed,
estimated or expected.
Press Release PDF:
http://hugin.info/131801/R/1609568/511261.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE
[HUG#1609568]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.05.2012 - 01:01 Uhr
Sprache: Deutsch
News-ID 1111495
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Allschwil
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 156 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actelion presents its strategy for value creation
"
steht unter der journalistisch-redaktionellen Verantwortung von
Actelion Pharmaceuticals Ltd (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
